Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) insider Mayukh Sukhatme sold 243,177 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $36.23, for a total transaction of $8,810,302.71. Following the transaction, the insider directly owned 18,630,739 shares of the company’s stock, valued at approximately $674,991,673.97. This trade represents a 1.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Mayukh Sukhatme also recently made the following trade(s):
- On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The stock was sold at an average price of $36.25, for a total transaction of $10,320,628.75.
- On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The stock was sold at an average price of $36.73, for a total transaction of $5,029,879.66.
Roivant Sciences Stock Down 1.5%
Shares of NASDAQ:ROIV opened at $36.84 on Friday. The company has a market cap of $26.61 billion, a PE ratio of -69.51 and a beta of 1.12. The company’s 50-day moving average price is $34.48 and its 200 day moving average price is $30.38. Roivant Sciences Ltd. has a fifty-two week low of $11.54 and a fifty-two week high of $37.97.
Institutional Investors Weigh In On Roivant Sciences
Hedge funds have recently made changes to their positions in the company. SBI Securities Co. Ltd. grew its position in Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP boosted its position in shares of Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after buying an additional 583 shares during the period. Kestra Advisory Services LLC purchased a new position in shares of Roivant Sciences during the fourth quarter valued at $47,000. Parallel Advisors LLC raised its position in Roivant Sciences by 33.7% during the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after buying an additional 520 shares during the period. Finally, CIBC Private Wealth Group LLC lifted its stake in Roivant Sciences by 7,614.3% in the 4th quarter. CIBC Private Wealth Group LLC now owns 2,700 shares of the company’s stock worth $59,000 after acquiring an additional 2,665 shares in the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.
Analyst Upgrades and Downgrades
ROIV has been the subject of a number of recent analyst reports. Citigroup increased their price objective on Roivant Sciences from $42.00 to $46.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Sanford C. Bernstein upgraded Roivant Sciences to a “strong-buy” rating in a research report on Wednesday, July 29th. Guggenheim increased their price target on Roivant Sciences from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Bank of America reissued a “neutral” rating on shares of Roivant Sciences in a report on Friday, July 31st. Finally, Weiss Ratings lowered shares of Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Roivant Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.14.
Get Our Latest Research Report on ROIV
About Roivant Sciences
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.
See Also
- Five stocks we like better than Roivant Sciences
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
